paper icon

PUBLICATIONS

SOT 2015 Poster: Differential Effect of Anesthetic on QT Interval Measurements in Guinea Pigs - Part 2 »Download


SOT 2014 Poster: Effect of Anesthetic on QT Interval Measurements in Guinea Pigs »Download


ACT 2013 Poster: PAH Induced by Semaxanib and Low Oxygen Environment: Time Course Pulmonary Artery Pressure Increases Measured by Telemetry »Download


TCT 2012 Poster: Veropaque, A Novel Contrast Formulation, Mitigates Contrast Induced Acute Kidney Injury »Download


EB 2012 Poster: Bosentan and Sildenafil Reduces PAH Induced by Semaxanib and Low Oxygen Environment »Download


EB 2012 Poster: Dronedarone Effects on Atrial and Ventricular Electrophysiology in Conscious Models »Download


PM101: A Cyclodextrin-Based Intravenous Formulation of Amiodarone
Devoid of Adverse Hemodynamic Effects

This study provides a useful model for the continued search for a safe and effective intravenous amiodarone formulation devoid of the hypotensive risk associated with the current commercial formulation. »Download


Comparison of the Cardiac Electrophysiology and General Toxicology
of Two Formulations of Intravenous Amiodarone in Dogs

Intravenous amiodarone (AIV) must be administered slowly after dilution to avoid hypotension, which is due to the cosolvents polysorbate 80 and benzyl alcohol used in its formulation. PM101 is a formulation of amiodarone devoid of these cosolvents, which enables bolus administration. We evaluated any potential toxicity or exaggerated adverse cardiac electrophysiologic effects of PM101 compared with AIV and control. »Download


The Hypotensive Effect of Intravenous Amiodarone is Sustained
Throughout the Maintenance Infusion Period

The objective of the present study was to determine whether the maintenance dose of the conventional formulation of intravenous amiodarone was associated with sustained hypotension throughout the dosing period. »Download


Advantages of the Perfused Isolated Rabbit Heart for the Assessment
of the Electrophysiologic and Hemodynamic Effects of Drug Candidates

This paradigm acts as a physiologically relevant bridge between purely in vitro assays and costly, resource-intensive whole-animal studies. The model has been used extensively in experimental cardiovascular investigations and it is a widely accepted surrogate for the study of human cardiac function. »Download  

 

paper icon

PUBLISHED COLLABORATIONS

Investigation of Mechanism of Drug-Induced Cardiac Injury
and Torsades de Pointes in Non-Human Primates

In collaboration with Hoffman-La Roche, CorDynamics conducted studies to determine the molecular mechanism of an arrhythmia found during the course of routine toxicological assessments. The compound RO5657, a CCR5 antagonist, was discovered to have the rare liability of inducing torsades de pointes (polymorphic ventricular arrhythmia) in normal, healthy animals. »Download


Pharmacological Characterization of KLYP961,
A Dual Inhibitor of Inducible and Neuronal Nitric Oxide Synthases

CorDynamics collaborated with the Kalypsys study of KLYP961. KLYP961 represents an ideal tool with which to probe the physiological role of NO derived from iNOS and nNOS in human pain and inflammatory states. KLYP961 has minimal off-target activity, desirable drug like properties such as pharmacokinetic profile, CYP-450 and hERG activities. In addition, KLYP961 has efficacy in a range of pain/inflammation models both in rodents and non-human primates. »Download


Monocrotaline Induced Pulmonary Arterial Hypertension in Rats
In collaboration with Corridor Pharmaceuticals, CorDynamics demonstrated the novel serotonin receptor antagonist C-122 prevents monocrotaline induced pulmonary arterial hypertension in rats in a paper published in the European Journal of Pharmacology. The authors hypothesized that interfering with serotonin function may reduce the vascular remodeling and hemodynamic changes that occur in this preclinical model. »Download